Cyclacel Pharmaceuticals Inc

NASDAQ:CYCCUnited States

NASDAQ FSI:D. Deficient (Issuer failed to meet continued listing requirements)

Cyclacel Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in developing cancer medicines based on cell cycle, transcriptional regulation and mitosis control biology. The Company is focused on the field of cancer cell cycle biology with a vision to improve patient healthcare by translating insights in cancer biology into medicines that can overcome resistance and ultimately increase a patient’s overall survival. The Company's pipeline includes Fadraciclib, CYC140 and Sapacitabine. The Fadraciclib is a cyclin dependent kinase (CDK) inhibitor selectively targeting Cyclin Dependent Kinase 2 (CDK2) and Cyclin-dependent kinase 9 (CDK9). The CYC140 is a novel, small molecule, selective and potent PLK-centric inhibitor. The Company's Sapacitabine (CYC682) is an orally available nucleoside analogue with a DNA damage response (DDR) mechanism.

Contact Information

Headquarters

200 Connell Dr Ste 1500BERKELEY HEIGHTS, NJ, United States 07922-2811

Phone

908-517-7330

Fax

866-271-3466

Executives

Independent Chairman of the Board

Christopher Henney

President, Chief Executive Officer, Director

Spiro Rombotis

Chief Financial Officer, Chief Operating Officer, Executive Vice President - Finance, Secretary, Director

Paul Mcbarron

Senior Vice President, Chief Medical Officer

Mark Kirschbaum

Independent Director

Samuel Barker